P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

• Michel Delforge,
• Krina Patel,
• Laurie Eliason,
• Devender Dhanda,
• Ling Shi,
• Shien Guo,
• Thomas Marshall,
• Bertrand Arnulf,
• Michele Cavo,
• Ajay Nooka,
• Salomon Manier,
• Natalie Callander,
• Sergio Giralt,
• Hermann Einsele,
• Sikander Ailawadhi,
• Mihaela Popa Mckiver,
• Mark Cook,
• Paula Rodríguez-Otero

Affiliations

Michel Delforge

1 University Hospital Leuven, Leuven, Belgium

Krina Patel

2 The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Laurie Eliason

3 Bristol Myers Squibb, Princeton, NJ, United States

Devender Dhanda

3 Bristol Myers Squibb, Princeton, NJ, United States

Ling Shi

4 Evidera, Bethesada, MA

Shien Guo

4 Evidera, Bethesada, MA

Thomas Marshall

3 Bristol Myers Squibb, Princeton, NJ, United States

Bertrand Arnulf

5 Hôpital Saint-Louis, Paris, France

Michele Cavo

6 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

Ajay Nooka

7 Winship Cancer Institute, Emory University, Atlanta, GA, United States

Salomon Manier

8 Centre Hospitalier Universitaire de Lille, Lille, France

Natalie Callander

9 University of Wisconsin Health, Madison, WI, United States

Sergio Giralt

10 Memorial Sloan Kettering Cancer Center, New York, NY, United States

Hermann Einsele

11 Medizinische Klinik und Poliklinik II, Uniklinikum Würzburg, Würzburg, Germany

Sikander Ailawadhi

12 Mayo Clinic, Jacksonville, FL, United States

Mihaela Popa Mckiver

3 Bristol Myers Squibb, Princeton, NJ, United States

Mark Cook

13 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

Paula Rodríguez-Otero

14 Clínica Universidad de Navarra, Pamplona, Spain